Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 28 ·No. 28 ·2010-10-01 ·Pages e507-10

Kelly RJ, Carter C, Giaccone G

Abstract

暂无摘要

MeSH Terms

Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma, Non-Small-Cell Lung/drug therapy Disease Progression Humans Lung Neoplasms/drug therapy Male Middle Aged Neoplasm Staging Precision Medicine Quinazolinones/administration & dosage Trastuzumab Vinblastine/administration & dosage,analogs & derivatives Vinorelbine

Chemicals

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Quinazolinones dacomitinib Vinblastine Trastuzumab Vinorelbine

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Kelly Ronan J

National Cancer Institute, Mark O. Hatfield Clinical Research Center, Bethesda, MD, USA.

Carter Corey

Giaccone Giuseppe

References (21)

21 references, click to expand

HER2/neu expression in malignant lung tumors.
Semin Oncol. 2002 Feb;29(1 Suppl 4):51-8 PMID: 11894014
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
Cancer. 2005 Apr 15;103(8):1670-5 PMID: 15751020
Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis.
Cancer. 2005 May 1;103(9):1865-73 PMID: 15770690
Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors.
Med Oncol. 2009;26(2):151-6 PMID: 18855148
Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
J Clin Oncol. 2003 Jun 15;21(12):2227-9 PMID: 12748243
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Clin Cancer Res. 2007 Oct 15;13(20):6175-81 PMID: 17947484
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
N Engl J Med. 2006 Jun 15;354(24):2619-21 PMID: 16775247
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
EMBO J. 1997 Apr 1;16(7):1647-55 PMID: 9130710
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Cancer. 2005 Nov 15;104(10):2149-55 PMID: 16208701
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
J Clin Oncol. 2005 Aug 1;23(22):5007-18 PMID: 16051952
Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Cancer. 2001 Oct 1;92(7):1896-904 PMID: 11745263
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
J Clin Oncol. 2004 Apr 1;22(7):1180-7 PMID: 14981103
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Cancer Res. 2005 Mar 1;65(5):1642-6 PMID: 15753357
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Ann Oncol. 2004 Jan;15(1):19-27 PMID: 14679114
HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.
Clin Cancer Res. 2003 Nov 1;9(14):5238-43 PMID: 14614004
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
Lung Cancer. 2004 Apr;44(1):99-110 PMID: 15013588
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43 PMID: 14734462
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Cancer Res. 2007 Dec 15;67(24):11924-32 PMID: 18089823
Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4436s-4440s PMID: 16857824
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
Clin Cancer Res. 2001 Jul;7(7):1850-5 PMID: 11448895
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
Br J Cancer. 2002 May 6;86(9):1449-56 PMID: 11986780

Article Info

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abbr.

J Clin Oncol

ISSN

1527-7755

DOI

10.1200/JCO.2010.29.3126

Published

2010-10-01

Epub

2010-00-02

Pages

e507-10

Language

English

Region

United States

NLM ID

8309333

PMCID

PMC7301570

Subset

Grants

Intramural NIH HHS · Z01 BC011051 · United States

Intramural NIH HHS · ZIA BC011269 · United States

External Links

PubMed source DOI: 10.1200/JCO.2010.29.3126 PMC Full Text View journal details

Analysis Services

Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.

Contact

WeChat Official Account